sCD163 in PBC Patients - Assessment of Treatment Response

Launched by UNIVERSITY OF AARHUS · Oct 11, 2016

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to understand how patients with Primary Biliary Cholangitis (PBC) respond to a common treatment called Ursodeoxycholic Acid (UDCA). PBC is a long-term liver disease where the small bile ducts in the liver get damaged. While UDCA helps many patients, about 40% do not respond well to it. Researchers want to see if two markers in the blood, called sCD163 and sMR, can help predict which patients will benefit from UDCA.

To participate in this study, you must be newly diagnosed with PBC and have not started treatment with UDCA yet. Unfortunately, if you are under 18 years old, expect to live less than 6 months, have liver cancer, or need a liver transplant soon, you won't be eligible. If you join, you'll help researchers understand more about PBC and potentially improve future treatments for others. This study is currently recruiting participants of all genders aged 65 to 74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly diagnosed with Primary biliary cholangitis
• • No treatment with UDCA
• Exclusion Criteria:
• • Patient under 18 years
• • Expected lifetime under 6 months
• • Expected liver transplantation within 6 months
• • Liver cancer
• • Cirrhosis from other causes